On March 23, 2026, Gilead Sciences announced a definitive agreement to acquire Ouro Medicines in a deal potentially worth $2.175 billion. This acquisition underscores Gilead’s strategic push into transformative therapies for serious autoimmune diseases using advanced T-cell engager technology.
Financial and Technological Highlights:
-
Deal Structure: Gilead will pay $1.675 billion in upfront cash and up to $500 million in contingent milestones. Notably, Galapagos is partnering in the deal, funding 50% of the acquisition and development costs.
-
Lead Candidate OM336 (gamgertamig): The center of the deal is a BCMAxCD3 bispecific T-cell engager. It is designed to redirect a patient’s own T cells to deplete the BCMA-expressing plasma cells responsible for producing pathogenic autoantibodies.
-
“Immune Reset” Potential: Unlike traditional immunosuppressants that require lifelong use, OM336 offers the potential for durable, drug-free remission. Early data shows efficacy in rare antibody-mediated conditions such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
-
Regulatory Roadmap: The FDA has granted Fast Track and Orphan Drug designations for OM336 in its lead indications. Registrational studies are expected to commence in 2027.
Strategic Alliance with Galapagos: Galapagos will absorb substantially all of Ouro’s operating assets and employees while covering development costs through the start of registrational studies. Gilead retains sole worldwide commercialization rights (excluding Greater China) and will pay Galapagos royalties ranging from 20% to 23% of net sales.